Medical/Pharmaceuticals

Terumo Interventional Systems Announces Commercial Availability of Its ROADSAVER™ Carotid Stent System

– Innovative, dual-layer micromesh, closed-cell stent with the flexibility of an open-cell stent for maximizing clinical outcomes in carotid artery stenting procedures  – SOMERSET, N.J., May 27, 2025 /PRNewswire/ -- Terumo Interventional Systems (TIS), a division of Terumo Corporation, is please...

2025-05-28 01:40 2008

Alma Unveils Alma IQ at Eighth Global Alma Academy in Dubrovnik

The next-generation skin analysis platform, set to redefine the aesthetic consultation experience CAESAREA, Israel, May 27, 2025 /PRNewswire/ -- Alma , a Sisram Medical company and a global leader in energy-based medical and aesthetic solutions, has officially launchedA...

2025-05-27 13:00 2047

ZYLOX Unicorn™ Vascular Closure Device Receives Regulatory Approval in Indonesia

HANGZHOU, China, May 26, 2025 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge" or the "Company") today announced that its proprietary ZYLOX Unicorn™ Vascular Closure Device (VCD) has received regulatory approval inIndonesia. This marks the ZYLOX Unicorn™ Vascular Cl...

2025-05-27 10:14 1710

SeekInCare: New Multi-Omics Blood Test Shows Promise for Early Cancer Detection Across Multiple Cancer Types

SAN DIEGO, May 26, 2025 /PRNewswire/ -- A groundbreaking study published in the Journal of Molecular Diagnostics reports the successful clinical validation of SeekInCare®, a novel, non-invasive multi-omics blood test designed for the early detection of multiple cancer types. Developed by research...

2025-05-26 23:00 2299

Lunit Highlights AI's Role in Advancing Precision Oncology at ASCO 2025 with 12 Studies

SEOUL, South Korea, May 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that 12 studies featuring its AI-powered digital pathology solution will be presented at the 2025 American Society of Clinical Oncology (ASCO) ...

2025-05-26 21:00 2104

MGI Tech Showcases Comprehensive Multi-Omics Solutions at ESHG 2025 Milan

MILAN, May 26, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, unveiled cutting-edge multi-omics technologies at the European Society of Human Genetics (ESHG) 2025 conference inMilan. At Booth #31...

2025-05-26 18:30 1770

Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025

* DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with ORR of 84.2% * DZD6008, a BBB-penetrant 4th generation EGFR TKI, showed encouraging and durable anti-tumor activity with favorable safet...

2025-05-26 18:06 2049

VUNO Showcases DeepCARS® at AACN NTI 2025, Highlighting AI-Driven Cardiac Arrest Risk Prediction

– Company engages U.S. critical care professionals with data-driven early warning solution MARLBOROUGH, Mass., May 26, 2025 /PRNewswire/ -- VUNO, a global medical AI company, presented its flagship solution VUNO Med®–DeepCARS® at the 2025 National Teaching Institute & Critical Care Exposition (N...

2025-05-26 13:50 2079

World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial

SUZHOU, China, May 25, 2025 /PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy has received official approval from bothChina's N...

2025-05-26 09:00 2167

Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths

* YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1] * Celltrion previously received interchangeability (IC) designation for YUFLYMA® (adalimumab-aaty) in prefilled syringes (20mg & 80mg); Expanded interchangeabilit...

2025-05-24 01:47 4286

/DISREGARD RELEASE: Celltrion/

We are advised by Celltrion that journalists and other readers should disregard the news release, Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths, issued21-May-2025 over PR Newswire. ...

2025-05-24 00:01 4165

Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting

SHANGHAI, May 23, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including phase Ib/II clini...

2025-05-23 22:00 4192

41st WHO Sasakawa Health Prize Awarded to Denmark's Dr. Merete Nordentoft For Work on Suicide Prevention in Young People

TOKYO, May 23, 2025 /PRNewswire/ -- The 41st WHO Sasakawa Health Prize was presented to Danish psychiatrist Dr.Merete Nordentoft in recognition of her work on suicide prevention in young people, during a ceremony at the 78th World Health Assembly inGeneva on May 23.

2025-05-23 21:00 4244

UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's disease, in its Phase 1 study

SHANGHAI, May 23, 2025 /PRNewswire/ -- Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its proprietary Parkinson's disease cell drug UX-DA001 inChina in March 2025. The Phase I c...

2025-05-23 19:18 4751

Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting

CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), today announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC...

2025-05-23 12:21 3229

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, to...

2025-05-23 10:44 2227

Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting

Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, May 22, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI...

2025-05-23 08:00 3196

CARsgen's Satri-cel Abstract Available on ASCO Website

SHANGHAI, May 22, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the research results of the confirmatory Phase II clinical trial of satricabtagene autoleucel ("satri-...

2025-05-23 08:00 2136

Porton Advanced Announces Collaboration with TongEYE to Accelerate Development of iPSC-RPEC transplantation therapy

SUZHOU, China, May 22, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with TongEye Medical Technology (TongEYE), an innovator focusing on...

2025-05-22 21:00 2081

MGI Tech Unveils Next-Generation Automation Portfolio at SLAS Europe 2025 in Germany

HAMBURG, Germany, May 21, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences,  is proud to unveil its latest innovation, PrepALL, a flexible liquid handling system, along with the latest version of t...

2025-05-22 10:38 1893
1 ... 30313233343536 ... 248

Week's Top Stories